KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Recursion Pharmaceuticals (RXRX) Leases (2022 - 2025)

Recursion Pharmaceuticals' Leases history spans 4 years, with the latest figure at $45.3 million for Q4 2025.

  • For Q4 2025, Leases fell 31.18% year-over-year to $45.3 million; the TTM value through Dec 2025 reached $45.3 million, down 31.18%, while the annual FY2025 figure was $45.3 million, 31.18% down from the prior year.
  • Leases reached $45.3 million in Q4 2025 per RXRX's latest filing, down from $47.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $65.9 million in Q4 2024 to a low of $33.3 million in Q4 2022.
  • Average Leases over 4 years is $41.4 million, with a median of $35.3 million recorded in 2023.
  • Peak YoY movement for Leases: soared 95.7% in 2024, then tumbled 31.18% in 2025.
  • A 4-year view of Leases shows it stood at $33.3 million in 2022, then increased by 1.23% to $33.7 million in 2023, then skyrocketed by 95.7% to $65.9 million in 2024, then crashed by 31.18% to $45.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Leases are $45.3 million (Q4 2025), $47.8 million (Q3 2025), and $50.3 million (Q2 2025).